FDA blindsided by decision to allow more e-cigarettes and nicotine pouches

FDA senior officials were blindsided by leadership's decision to publish new guidelines allowing more unauthorized e-cigarettes and nicotine pouches onto the market without full regulatory vetting.

Objective Facts

Senior FDA officials in the tobacco center were blindsided by a recent decision that opens the door to allowing more unauthorized electronic cigarettes and nicotine pouches onto the U.S. market. The guidelines, posted days before former FDA Commissioner Marty Makary resigned, will allow companies to launch certain nicotine-based products before they've been fully vetted by regulators. Some FDA officials tasked with enforcing vaping regulations were not consulted on the changes and only learned of them the night before the document was published earlier this month. The vaping guidelines bypassed a federally required period that allows for public comment and revisions. Instead, the FDA published the finalized policy after months of complaints about Makary from industry lobbyists close to the White House. Eight days after Reynolds American donated $5 million to a Trump-backed super PAC, a Reynolds executive and two Reynolds lobbyists had lunch with Trump at his Florida golf club and reportedly pressed the president on FDA regulations. Trump pulled out his phone and called FDA Commissioner Marty Makary to complain. The policy shift represents a dramatic departure from established FDA procedure and generates significant concerns about internal process integrity.

Left-Leaning Perspective

Senator Chris Murphy (D-CT) excoriated the Trump administration for "corruption," tweeting a detailed timeline of the donation, Mar-a-Lago meeting, Trump's call to RFK Jr., and the FDA policy change. The American Lung Association's Ranjana Caple stated the timing "raises serious concerns about priorities and commitment to protecting kids," arguing the agency is "waving the white flag rather than restoring order to the marketplace." The Rachel Maddow Show reported that tobacco executives and lobbyists leaned on Trump to expand access to flavored vaping products that Makary had resisted, and by some accounts Trump personally "upbraided" the FDA commissioner on the matter before the agency authorized the fruit-flavored vapes shortly after Trump's intervention. Mitch Zeller, former FDA tobacco director, stated it "begs the question of whether the true subject matter experts may have actually opposed this policy and were ordered to do it anyway," noting this affects "the ability of the public to have trust and faith in institutions like FDA." Zeller called the guidance troubling because the FDA skipped the process of issuing a draft and allowing public comments before publishing its final guidance, noting it is "alarming" because typically the FDA only goes straight to final guidance if there's a public health emergency. The American Lung Association's Caple said the guidance effectively allows companies to keep illicit products on the market, arguing that while the FDA claims it lacks enforcement resources, "the answer isn't to normalize illicit products on the market". Left-leaning coverage emphasizes the apparent pay-to-play sequence and the sidelining of FDA career scientists. It downplays harm-reduction arguments and focuses primarily on youth protection risks and the procedural irregularities that bypass public input. Coverage tends to frame this as regulatory capture by the tobacco industry rather than as a pragmatic policy shift.

Right-Leaning Perspective

Conservative and harm-reduction advocates have supported FDA discretion on vaping as a practical response to enforcement limits and scientific evidence. A Reason commentary noted that the latest National Youth Tobacco Survey found youth e-cigarette use at 5.9 percent in 2024, down from 7.7 percent in 2023 and the lowest level in a decade, arguing Makary should focus on the 28.8 million adult smokers who need access to alternatives. An AEI analysis argued that the sharp decrease in youth vaping from 2020 to 2025 coincided with a dramatic increase in flavored vaping products available in the market, and "if there were in fact a correlative relationship between the availability of 'youth-appealing flavors' and youth use, recent real-world evidence would show it to be a near-perfectly negative relationship". Jonathan Foulds, a tobacco-addiction specialist at Penn State University, said the FDA is "just deluged by illegal products coming across the border" and "making it clear what should be common sense: 'We're going to focus on the worst actors.'" A Taxpayers Protection Alliance analysis argued that limited legal availability of flavored products does not eliminate demand but instead pushes consumers toward unregulated markets without quality controls or age restrictions, noting that the FDA's restrictive approach may have contributed to the very youth access issues it is trying to prevent, and that a more open and regulated market would make it easier to control product standards and restrict underage sales. Right-leaning coverage emphasizes pragmatism about the illicit market's dominance, scientific evidence of harm reduction, and the practical ineffectiveness of flavor bans given market realities. It downplays the procedural concerns and focuses on adult smoker needs rather than youth protection risks as the primary policy consideration.

Deep Dive

The story's specific angle centers on **FDA process failure and internal accountability**, not whether vaping itself is good or bad. FDA officials tasked with enforcing vaping regulations were not consulted on the changes and only learned of them the night before publication, and the document's sudden appearance sparked internal confusion about how the policy came about and who authorized it. The guidelines bypassed a federally required public comment period and were published after months of complaints from industry lobbyists close to the White House. This represents a genuine departure from FDA standard procedure that transcends the substantive policy debate. The timing is striking: eight days after Reynolds American donated $5 million to a Trump-backed super PAC, a Reynolds executive and lobbyists met with Trump at his golf club and pressed him on FDA regulations. Trump pulled out his phone and called FDA Commissioner Makary to complain. Left critics read this as corruption; right-leaning sources either don't address it or argue the policy outcome is correct on the merits regardless of motivation. What each perspective gets right: The left correctly identifies that the procedure violated established FDA protocols and that the decision sequence appears to correlate with corporate donations—raising legitimate questions about institutional independence. The right correctly notes that underage vaping has fallen to its lowest level in more than 10 years, that the FDA is deluged by illegal products from China, and that adult smokers have legitimate harm-reduction needs. What each perspective omits: Left-leaning coverage downplays the real enforcement challenge posed by illicit products and the evidence supporting harm reduction for adult smokers. Right-leaning sources largely avoid defending or addressing the procedural irregularities and the absence of internal FDA consultation—the core issue of institutional accountability, regardless of policy substance. The key unresolved question: Was this a necessary pragmatic response to an overwhelming enforcement problem, or a breakdown in regulatory independence? The evidence supports that both the procedural failure and the illicit market problem are real.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

FDA blindsided by decision to allow more e-cigarettes and nicotine pouches

FDA senior officials were blindsided by leadership's decision to publish new guidelines allowing more unauthorized e-cigarettes and nicotine pouches onto the market without full regulatory vetting.

May 25, 2026· Updated May 26, 2026
What's Going On

Senior FDA officials in the tobacco center were blindsided by a recent decision that opens the door to allowing more unauthorized electronic cigarettes and nicotine pouches onto the U.S. market. The guidelines, posted days before former FDA Commissioner Marty Makary resigned, will allow companies to launch certain nicotine-based products before they've been fully vetted by regulators. Some FDA officials tasked with enforcing vaping regulations were not consulted on the changes and only learned of them the night before the document was published earlier this month. The vaping guidelines bypassed a federally required period that allows for public comment and revisions. Instead, the FDA published the finalized policy after months of complaints about Makary from industry lobbyists close to the White House. Eight days after Reynolds American donated $5 million to a Trump-backed super PAC, a Reynolds executive and two Reynolds lobbyists had lunch with Trump at his Florida golf club and reportedly pressed the president on FDA regulations. Trump pulled out his phone and called FDA Commissioner Marty Makary to complain. The policy shift represents a dramatic departure from established FDA procedure and generates significant concerns about internal process integrity.

Left says: Senator Chris Murphy and other Democrats called the decision "corruption", while health advocates like the American Lung Association said the FDA was "waving the white flag" on protecting youth.
Right says: Conservative and harm-reduction advocates argue youth vaping is declining and at lowest levels in a decade, so FDA should focus on the 28.8 million adult smokers who need alternatives to cigarettes. Some experts say the FDA is simply being pragmatic about illegal products flooding the market and focusing enforcement on "the worst actors".
✓ Common Ground
Both sides acknowledge that underage vaping among U.S. teenagers has fallen to its lowest level in more than 10 years, though they differ sharply on what policy conclusion follows.
Several voices across the spectrum—including tobacco-addiction specialist Jonathan Foulds and others—agree that most health researchers accept that e-cigarettes are significantly less harmful than traditional cigarettes and that the FDA has struggled for over a decade to police a market deluged by illegal products.
There appears to be shared recognition that unauthorized vapes are widely available at gas stations, vape shops, and convenience stores, with the U.S. market flooded for years by unauthorized vapes containing mango, gummy bear, strawberry and dozens of other flavors.
A number of commentators, regardless of leaning, note that the lack of internal consultation with subject matter experts raises transparency concerns, with Mitch Zeller noting the process "begs the question of whether the true subject matter experts may have actually opposed this policy and were ordered to do it anyway".
Objective Deep Dive

The story's specific angle centers on **FDA process failure and internal accountability**, not whether vaping itself is good or bad. FDA officials tasked with enforcing vaping regulations were not consulted on the changes and only learned of them the night before publication, and the document's sudden appearance sparked internal confusion about how the policy came about and who authorized it. The guidelines bypassed a federally required public comment period and were published after months of complaints from industry lobbyists close to the White House. This represents a genuine departure from FDA standard procedure that transcends the substantive policy debate.

The timing is striking: eight days after Reynolds American donated $5 million to a Trump-backed super PAC, a Reynolds executive and lobbyists met with Trump at his golf club and pressed him on FDA regulations. Trump pulled out his phone and called FDA Commissioner Makary to complain. Left critics read this as corruption; right-leaning sources either don't address it or argue the policy outcome is correct on the merits regardless of motivation.

What each perspective gets right: The left correctly identifies that the procedure violated established FDA protocols and that the decision sequence appears to correlate with corporate donations—raising legitimate questions about institutional independence. The right correctly notes that underage vaping has fallen to its lowest level in more than 10 years, that the FDA is deluged by illegal products from China, and that adult smokers have legitimate harm-reduction needs.

What each perspective omits: Left-leaning coverage downplays the real enforcement challenge posed by illicit products and the evidence supporting harm reduction for adult smokers. Right-leaning sources largely avoid defending or addressing the procedural irregularities and the absence of internal FDA consultation—the core issue of institutional accountability, regardless of policy substance. The key unresolved question: Was this a necessary pragmatic response to an overwhelming enforcement problem, or a breakdown in regulatory independence? The evidence supports that both the procedural failure and the illicit market problem are real.

◈ Tone Comparison

Left-leaning outlets use language of institutional failure and corruption: Senator Murphy framed it as "Here's how the corruption works", while the American Lung Association used "waving the white flag" suggesting defeat. Right-leaning sources use pragmatic, evidence-based framing: Foulds described the policy as common sense focusing on "the worst actors", and the Taxpayers Protection Alliance called it "a welcome shift in tone".